-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Yiling Wanzhou International Pharmaceutical's 4 types of generic applications for felodipine sustained-release tablets entered the "approval" status.
At present, the company has 6 cardiovascular system chemical products.
If the product is successfully approved, it is expected to be A new addition to the company
.
Figure 1: Yiling's Felodipine Sustained-Release Tablets Application Progress Source: Minet.
com's new database Figure 2: Felodipine's sales (unit: 100 million yuan) Source: Minet.
com China's public medical institutions' terminal competition pattern Felodipine is A long-acting dihydropyridine calcium antagonist for the treatment of hypertension
.
According to data from Minet.
com, in 2020, in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), the sales of felodipine have exceeded 2.
5 billion yuan.
Among the TOP20 generic names of vascular system drugs, the ranking rose to seventh
.
At present, the best-selling dosage forms of felodipine on the market include ordinary tablets, sustained-release tablets and capsules
.
Figure 3: Felodipine products that have been reviewed Source: Minet's new version of the database In recent years, under the impact of domestic generic drugs, AstraZeneca's market share has declined rapidly, from 82.
94% in 2013 to 59.
49% in the first half of 2021 %, it can be seen that the market potential of domestic brands is huge.
At present, 2 companies have reviewed felodipine sustained-release tablets, and they have not been included in the national procurement catalog
.
Note: The original text has been deleted.
Source: Minet database, CDE official website, etc.
Statistics are as of March 23.
If there are any omissions, please correct me!
At present, the company has 6 cardiovascular system chemical products.
If the product is successfully approved, it is expected to be A new addition to the company
.
Figure 1: Yiling's Felodipine Sustained-Release Tablets Application Progress Source: Minet.
com's new database Figure 2: Felodipine's sales (unit: 100 million yuan) Source: Minet.
com China's public medical institutions' terminal competition pattern Felodipine is A long-acting dihydropyridine calcium antagonist for the treatment of hypertension
.
According to data from Minet.
com, in 2020, in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), the sales of felodipine have exceeded 2.
5 billion yuan.
Among the TOP20 generic names of vascular system drugs, the ranking rose to seventh
.
At present, the best-selling dosage forms of felodipine on the market include ordinary tablets, sustained-release tablets and capsules
.
Figure 3: Felodipine products that have been reviewed Source: Minet's new version of the database In recent years, under the impact of domestic generic drugs, AstraZeneca's market share has declined rapidly, from 82.
94% in 2013 to 59.
49% in the first half of 2021 %, it can be seen that the market potential of domestic brands is huge.
At present, 2 companies have reviewed felodipine sustained-release tablets, and they have not been included in the national procurement catalog
.
Note: The original text has been deleted.
Source: Minet database, CDE official website, etc.
Statistics are as of March 23.
If there are any omissions, please correct me!
